[1. She Z-G, Chen H-Z, Yan Y, Li H, Liu D-P. The Human Paraoxonase Gene Cluster as a Target in the Treatment of Atherosclerosis. Antioxid Redox Signal. 2012 Mar 15;16(6):597-632.10.1089/ars.2010.3774]Search in Google Scholar
[2. Kedage V, Muttigi MS, Shetty MS, Suvarna R, Rao SS, Joshi C, et al. Serum Paraoxonase 1 Activity Status in Patients with Liver Disorders. Saudi J Gastroenterol. 2010;16(2):79-83.10.4103/1319-3767.61232]Search in Google Scholar
[3. Beltowski J, Wójcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis. 2003;170:21-9.10.1016/S0021-9150(03)00236-3]Search in Google Scholar
[4. Audikovszky M, Pados G, Seres I, Harangi M, Fülöp P, Katona E, et al. Orlistat increases serum paraoxonase activity in obese patients. Nutr Metab Cardiovasc Dis. 2007;17:268-73.10.1016/j.numecd.2006.03.00417134960]Search in Google Scholar
[5. Veiga L, Silva-Nunes J, Melão A, Oliveira A, Duarte L, Brito M. Q192R polymorphism of the paraoxonase-1 gene as a risk factor for obesity in Portuguese women. Eur J Endocrinol. 2011;164:213-8.10.1530/EJE-10-082521078685]Search in Google Scholar
[6. Martínez-Salazar MF, Almenares-López D, García- Jiménez S, Sánchez-Alemán MA, Juantorena-Ugás A, Ríos C, et al. Relationship between the paraoxonase (PON1) L55M and Q192R polymorphisms and obesity in a Mexican population: a pilot study. Genes Nutr. 2011;6:361-8.10.1007/s12263-011-0215-0319784721484160]Search in Google Scholar
[7. Camps J, Marsillach J, Joven J. Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol. 2009;15(16):1929-33.10.3748/wjg.15.1929267508119399923]Search in Google Scholar
[8. Chedid R, Gannagé-Yared MH, Khalifé S, Halaby G, Zoghbi F. Impact of different metabolic syndrome classifications on the metabolic syndrome prevalence in a young Middle Eastern population. Metabolism. 2009;58(6):746-52.10.1016/j.metabol.2008.11.01419446111]Search in Google Scholar
[9. Paşca SP, Dronca E, Nemeş B, Kaucsár T, Endreffy E, Iftene F, et al. Paraoxonase 1 activities and polymorphisms in autism spectrum disorders. J Cell Mol Med. 2010;14:600-7.]Search in Google Scholar
[10. Altuner D, Ates I, Suzen SH, Koc GV, Aral Y, Karakaya A. The relationship of PON1 QR 192 and LM polymorphisms with serum paraoxonase activities of Turkish diabetic patients. Toxicol Ind Health. 2011;27(10):873-8.10.1177/074823371139931721505009]Search in Google Scholar
[11. Grdic Rajkovic M, Rumora L, Barisic K. The paraoxonase 1,2 and 3 in humans. Biochemia Medica. 2011;21(2):122-30.10.11613/BM.2011.020]Search in Google Scholar
[12. ATP III Final Report PDF: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation. 2002;106:3143.10.1161/circ.106.25.3143]Search in Google Scholar
[13. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5.10.1161/CIRCULATIONAHA.109.19264419805654]Search in Google Scholar
[14. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization (accessed in February 2013). Available at http://whqlibdoc.who.int/trs/WHO_TRS_894.pdf.]Search in Google Scholar
[15. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983;35(2):214-27.]Search in Google Scholar
[16. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2004;44:6371-82.10.1021/bi047440d15835926]Search in Google Scholar
[17. Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD.Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting CAD risk in North-West Indian Punjabis. PLoS One. 2011;6(5):e17805.10.1371/journal.pone.0017805310120221629682]Search in Google Scholar
[18. Kotani K, Sakane N, Sano Y, Tsuzaki K, Matsuoka Y, Eqawa K et al. Change on the Physiological Lactonase Activity of Serum Paraoxonase 1 by Diet Intervention for Weight Loss in healthy Overweight and Obese Women. J Clin Biochem Nutr. 2009; 45(3):329-34.10.3164/jcbn.09-26277125519902024]Search in Google Scholar
[19. Kordi-Tamandani DM, Hashemi M, Sharifi N, Kaykhaei MA, Torkamanzehi A. Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome. Mol Biol Rep. 2012;39:937-43.10.1007/s11033-011-0819-x21573798]Search in Google Scholar
[20. Gorshunskaya MY, Karachentsev YI, Atramentova LA, Tyzhnenko TV, Kravchun NA, Pochernyaev AK, et al. Q192R polymorphism of PON-1 gene in type 2 diabetes patients. Cytol Genet. 2011 Feb 1;45(1):38-40.10.3103/S0095452711010087]Search in Google Scholar
[21. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology; 2005;69:541-50.10.1016/j.bcp.2004.08.02715670573]Search in Google Scholar
[22. Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR, et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation.Eur J Endocrinol 2011;162(3):535-41.10.1530/EJE-09-073220022940]Search in Google Scholar
[23. Rogulj D, Konjevoda P, Milić M, Mladinić M, Domijan AM. Fatty liver index as an indicator of metabolic syndrome. Clin Bioche. 2012;45(1-2):68-71.10.1016/j.clinbiochem.2011.10.01422056738]Search in Google Scholar
[24. Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V. HDL-paraoxonase and Membrane Lipid Peroxidation: A Comparison Between Healthy and Obese Subjects.Obesity. 2010;18(6):1079-84.10.1038/oby.2009.33819834469]Search in Google Scholar
[25. Roest M, van Himbergen TM, Barendrecht AB, Peeters PH, van der Schouw YT, Voorbij HA. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest. 2007;37:187-96.10.1111/j.1365-2362.2007.01769.x17359486]Search in Google Scholar